Challenges and Opportunities in Biotherapies and Bioproduction - an EIB Investment Perspective
The field of biotechnology is characterized by rapid advancements and breakthrough innovations. This dynamism poses unique challenges. The need to keep up with technological advancements, regulatory requirements, and shifting market dynamics demands substantial financial commitments and a forward-th...
Na minha lista:
| Auteurs principaux: | , , |
|---|---|
| Formato: | Article ou chapitre numérique |
| Idioma: | Français |
| Publicado em: |
2023
|
| Acesso em linha: | Accès Université d'Orléans et IFPM Accès Université d'Orléans et IFPM |
| id |
cairn-RINDU1_234_0056 |
|---|---|
| record_format |
cairn |
| spelling |
cairn-RINDU1_234_0056RINDU1Annales des Mines - Réalités industrielles https://stm.cairn.info/revue-realites-industrielles-2023-4-page-56?lang=en https://doi.org/10.3917/rindu1.234.0056 Challenges and Opportunities in Biotherapies and Bioproduction - an EIB Investment Perspective Piovesan, LauraNiculescu, CristinaIansante, Valeria2023 fre Annales des Mines - Réalités industrielles | ovembre 2023 | 4 | 2023-11-09 | p. 56-59 | 1148-7941 RINDU1_23499 The field of biotechnology is characterized by rapid advancements and breakthrough innovations. This dynamism poses unique challenges. The need to keep up with technological advancements, regulatory requirements, and shifting market dynamics demands substantial financial commitments and a forward-thinking approach. Although investment in advanced therapies has reached a record high of over $20 billion/year in 2020 and 2021, venture capital investment in biotech declined by 30-40% in 2022. Given the sector’s strategic importance, the European Investment Bank (EIB) is committed to playing a major role in developing a resilient and zero-emission biotechnology and bioproduction industry. The Bank is supporting the field with a holistic approach across the entire value chain, from raw material supply to research, development and bioproduction. The EU bank is the biggest venture debt provider to the life sciences sector in Europe with a portfolio of over €2.7 billion, supporting more than 100 innovative companies, almost half of which are in the biotechnology space.Cairn restricted access |
| language |
Français |
| format |
Article ou chapitre numérique |
| building |
0/Bibliothèque numérique/ 1/Bibliothèque numérique/Cairn/ |
| description |
The field of biotechnology is characterized by rapid advancements and breakthrough innovations. This dynamism poses unique challenges. The need to keep up with technological advancements, regulatory requirements, and shifting market dynamics demands substantial financial commitments and a forward-thinking approach. Although investment in advanced therapies has reached a record high of over $20 billion/year in 2020 and 2021, venture capital investment in biotech declined by 30-40% in 2022. Given the sector’s strategic importance, the European Investment Bank (EIB) is committed to playing a major role in developing a resilient and zero-emission biotechnology and bioproduction industry. The Bank is supporting the field with a holistic approach across the entire value chain, from raw material supply to research, development and bioproduction. The EU bank is the biggest venture debt provider to the life sciences sector in Europe with a portfolio of over €2.7 billion, supporting more than 100 innovative companies, almost half of which are in the biotechnology space. |
| author |
Piovesan, Laura Niculescu, Cristina Iansante, Valeria |
| spellingShingle |
Piovesan, Laura Niculescu, Cristina Iansante, Valeria Challenges and Opportunities in Biotherapies and Bioproduction - an EIB Investment Perspective |
| author_facet |
Piovesan, Laura Niculescu, Cristina Iansante, Valeria |
| author_sort |
Piovesan, Laura |
| title |
Challenges and Opportunities in Biotherapies and Bioproduction - an EIB Investment Perspective |
| title_short |
Challenges and Opportunities in Biotherapies and Bioproduction - an EIB Investment Perspective |
| title_full |
Challenges and Opportunities in Biotherapies and Bioproduction - an EIB Investment Perspective |
| title_fullStr |
Challenges and Opportunities in Biotherapies and Bioproduction - an EIB Investment Perspective |
| title_full_unstemmed |
Challenges and Opportunities in Biotherapies and Bioproduction - an EIB Investment Perspective |
| title_sort |
challenges and opportunities in biotherapies and bioproduction - an eib investment perspective |
| publishDate |
2023 |
| container_title |
|
| container_issue |
|
| url |
https://ezproxy.univ-orleans.fr/login?url=https://stm.cairn.info/revue-realites-industrielles-2023-4-page-56?lang=en https://ezproxy.univ-orleans.fr/login?url=https://doi.org/10.3917/rindu1.234.0056 |
| _version_ |
1877246680946966528 |